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adiotherapy can lead to both 
acute and late side effects, 
the former occurring over a 
timescale of weeks and then subsiding. 
Late effects occur months or even years 
after cessation of treatment and often 
show continuous progression with 
time. With conventionally fractionated 
radiotherapy, the late side effects 
usually limit the dose. 
    There are clear differences between 
patients regarding side effects: 
some patients appear to tolerate the 
treatment well, while others develop 
severe symptoms. Radiotherapy 
dose schedules have therefore been 
designed on past experience so that no 
more than 5%–10% of patients develop 
such severe side effects. 
    The question that has occupied 
radiation oncologists and scientists for 
many years is: what is different about 
the patients who develop the severe 
side effects? If we knew this, these 
patients could be given alternative 
schedules, doses, or treatments in 
order to produce more tolerable 
effects. In addition, and perhaps more 
importantly, the remaining majority 
of patients could be given a higher 
dose, leading to higher cure rates [1]. 
The question is therefore potentially 
important, but has not been an easy 
one to answer.
    Can Lymphocyte Response Predict 
Patient Morbidity?
    In a new study published in   PLoS 
Medicine  , J. Peter Svensson and 
colleagues present an intriguing 
attempt to elucidate genetic factors 
involved in late radiation toxicity 
[2]. Their approach was to look 
at differences in gene expression 
in lymphocytes of patients treated 
for prostate cancer. They hoped to 
discriminate patients with severe late 
radiation complications following 
radiotherapy (“over-responders” 
[OR]) from patients without such 
complications (“non-responders” 
[NR]). The OR group showed severe 
late complications of rectum and/or 
bladder, tissues which are unavoidably 
included in the radiation ﬁ  eld. Twenty-
one over-responders and 17 non-
responders participated in the primary 
classiﬁ  cation study. Twelve patients 
(6 ORs and 6 NRs) were used for 
independent validation.
    Peripheral blood lymphocytes 
from both the NR and OR groups 
were stimulated to proliferate with 
phytohaemagglutinin for two days. 
The lymphocytes were irradiated with 
2 Gy (the standard daily radiotherapy 
dose) and then RNA was extracted 
24 hours later for microarray analysis. 
Changes in gene expression resulting 
from the ex vivo irradiation were 
found to correlate with OR and NR 
status, although the performance 
of the classiﬁ  er was only moderate 
(the classiﬁ  er based on the radiation 
response of separate genes correctly 
classiﬁ  ed 63% of the patients). 
Better performance was achieved by 
considering sets of genes on speciﬁ  c 
functional pathways based on the Gene 
Ontology categories, including those 
for apoptosis, protein metabolism 
and ubiquitination, development, and 
stress signaling. Such gene sets were 
able to predict OR and NR status with 
an 83% accuracy. If validated, this 
would represent a step forward for the 
radiation oncologist.
  Strengths  and  Weaknesses 
of the Study
    There are two major strengths of this 
study. The ﬁ  rst is the selection of a 
good number of over-responders (27) 
from an initially large series (800) of 
patients treated in a single institute for 
prostate cancer. Identifying and then 
collecting material for analysis from 
this relatively homogeneously treated 
group is a valuable achievement. 
Second, the analysis of sets of 
functionally related genes, in addition 
to the usual approach of treating each 
gene separately, was clearly a step in 
the right direction, a trend now seen in 
many microarray studies.
    Paradoxically, the number of patients 
in the study is also a weakness. The 
number of events (serious side effects) 
eventually found and used for the 
training series was not large (21) and 
the validation population was small 
(6 ORs + 6 NRs). This was reﬂ  ected 
in a moderate performance on the 
validation group, eight of 12 being 
correctly predicted, not signiﬁ  cantly 
different from random chance. As 
admitted by the authors, part of this 
poor performance may have been due 
to slight differences in the handling 
of lymphocytes. Further studies are 
therefore required to see if these 
intriguing, preliminary results hold up. 
As with all microarray studies, ﬁ  nding 
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a classiﬁ  er in a training group is not 
difﬁ  cult. Finding a robust predictor 
withstanding validation in independent 
trials has turned out to be a lot more 
challenging.
  Why  Lymphocytes?
    If these results do hold up after further 
investigation, another question arises. 
The normal tissues damaged by 
radiation in this study were bladder 
and rectum. Some dose to these organs 
cannot be avoided, even by modern 
conformal radiotherapy. The question 
is: why should gene expression in a 
lymphocyte predict what will happen 
in these different and complex tissues, 
comprising largely epithelial, stromal, 
and vascular cells? The assumption 
is that there are underlying genetic 
factors governing the response of most 
or all tissues in the body to radiation. 
This is not immediately obvious. 
Radiation pathogenesis in such tissues 
depends on a number of factors, 
including damage to parenchymal cells 
and vasculature, and often involves 
various cytokines (e.g., TGF-beta) [3]. 
These factors will not be involved, or 
will only be involved to a lesser extent, 
in the response of lymphocytes.
    In defense of Svensson and 
colleagues’ approach, at least 
two studies have shown that the 
extent of cytogenetic damage in 
lymphocytes irradiated ex vivo 
correlates with normal tissue 
damage after radiotherapy [4,5]. 
Correlations of cytogenetic damage 
with gene expression would then 
support the present approach. 
There is little information on this, 
although it is logical to assume that 
intrinsic radiosensitivity differences 
will be reﬂ  ected in expression or 
function of the many genes affecting 
radiosensitivity. Reiger and colleagues 
[6] showed that expression changes 
in lymphoblastoid lines derived 
from patients and irradiated ex vivo 
correlated with radiation-induced 
morbidity, although again the study was 
small (14 patients).
    Questions and Future Directions
    Tissue and vascular factors undoubtedly 
inﬂ  uence the pathogenesis of normal 
tissue damage, and can vary between 
patients. Lymphocyte expression 
studies will not address these factors. 
If lymphocyte gene expression indeed 
turns out to be highly predictive in 
further investigations, it would imply 
that such tissue-related factors play only 
a minor role, which would represent a 
surprising and interesting ﬁ  nding. 
    More probably, tissue factors, maybe 
organ speciﬁ  c, will be found to play a 
role, and will eventually also need to 
be taken into account in any predictive 
test. Assuming genetic factors 
determine normal tissue damage, 
these could indeed be analyzed in 
lymphocytes, but at the DNA level. 
Single nucleotide polymorphisms, for 
example, have already shown some 
promise in predicting normal tissue 
morbidity [7]. Using lymphocytes for 
this purpose may be more fruitful than 
analyzing gene expression, but time will 
tell. The statistical power of Svensson 
and colleagues’ study is too low to 
warrant unbridled optimism at present, 
although it will surely stimulate further 
investigations and hopefully lead to 
improvements in radiotherapy.   
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